For patients with non-small cell lung cancer (NSCLC) harboring specific molecular alterations, such as epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, targeted therapies offer the promise of prolonged disease control and improved survival outcomes [43]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.